FDA Approves New Drugs for Endometrial Cancer and Ph-Negative BCP ALL

Tuesday, 18 June 2024 | Women's Cancers

The Food and Drug Administration (FDA) has approved new treatments for endometrial cancer and Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (Ph-negative BCP ALL). These advancements promise to enhance therapeutic options and improve outcomes for patients with these challenging conditions.

To continue, please login or sign up first